<DOC>
	<DOC>NCT00915590</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety of topical Interleukin-1-Receptor Antagonist in treatment of corneal neovascularization.</brief_summary>
	<brief_title>Topical IL-1-Ra for Treatment of Corneal Neovascularization</brief_title>
	<detailed_description />
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Ability to provide written informed consent and comply with study assessments for the full duration of the study Age &gt; 18 years Patients with superficial or deep corneal NV that extends farther than 1 mm from the limbus Patients are in generally good stable overall health • Has received treatment with antiVEGF agents (topical, intraocular or systemic) within 30 days of study entry Corneal or ocular surface infection within 30 days prior to study entry• Ocular or periocular malignancy Contact lens (excluding bandage contact lens) use within 2 weeks prior to study entry Persistent epithelial defect (&gt;1mm and ≥14 days duration) within 2 weeks prior to study entry Intravitreal or periocular steroids within 2 weeks prior to study entry Change in dose/frequency of topical steroids and/or NSAIDs within 2 weeks prior to study entry Pregnancy (positive pregnancy test) or lactation Premenopausal women not using contraception Signs of current infection, including fever and current treatment with antibiotics Participation in another simultaneous medical investigation or trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>